Treatment with Upadacitinib in Difficult-to-Treat (D2T) Psoriatic Arthritis (PsA): A National Multicenter Study of the First 134 Patients in Clinical Practice

Treatment with Upadacitinib in Difficult-to-Treat (D2T) Psoriatic Arthritis (PsA): A National Multicenter Study of the First 134 Patients in Clinical Practice

Upadacitinib has demonstrated efficacy in psoriatic arthritis in clinical trials, but its real-world performance in difficult-to-treat PsA remains underexplored. This observational, multicenter, open-label study evaluated the efficacy and safety of upadacitinib in 134 patients with psoriatic arthrit...

Full description

Saved in:
Bibliographic Details
Main Authors: Eva Galíndez-Agirregoikoa, Diana Prieto-Peña, Maria Luz García-Vivar, Joaquin Maria Belzunegui Otano, Beatriz Joven-Ibáñez, Cristina Vergara-Dangond, Marina Pavía-Pascual, Irati Urionaguena-Onaindia, Lucia Vega Alvarez, M. Ángeles Puche Larrubia, Consuelo Ramos Giráldez, Rosario Garcia-Vicuña, Vega Jovani, Angels Martínez-Ferrer, Mireia Moreno Martínez-Losa, Teresa González Hernández, Raquel Almodóvar González, Ana Urruticoechea-Arana, Cristina Macía-Villa, Inigo Gorostiza, Ricardo Blanco Alonso, Upadacitinib PsA Clinical Practice COLLABORATIVE STUDY GROUP
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Sci
Subjects:
biologic therapy
clinical practice
psoriatic arthritis
real-world data
upadacitinib
JAK inhibitor
Online Access:https://www.mdpi.com/2413-4155/7/2/67
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2413-4155/7/2/67

Similar Items